Nishant Vision Mohan

Dr. Nishant Vision Mohan


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 December 2025 in Medicina
Verified
Journal Article
Open access
PDF file
Miguel Antonio BusquetsMiguel Antonio Busquets
Miguel Antonio Busquets
RGRichard A. Garfinkel
Richard A. Garfinkel
DSDeepak Sambhara
Deepak Sambhara
NMNishant Vision Mohan
Nishant Vision Mohan
KNKester Nahen
Kester Nahen
Anat LoewensteinAnat Loewenstein
Anat Loewenstein
The management of age-related macular degeneration (AMD) presents a significant challenge attributable to high disease heterogeneity. Patient realization of symptoms is poor and it is urgent to treat before permanent anatomic damage results in vision loss. This is true for the initial conversion from non-exudative intermediate AMD (iAMD) to exudative AMD (nAMD), and for the recurrence of nAMD undergoing treatment. Starting from the essential requirements that any practical solution needs to fulfill, we will reflect on how persistent navigation towards innovative solutions during a 25-year journey yielded significant advances towards improvements in personalized care. An early insight was that the acute nature of AMD progression requires frequent monitoring and therefore diagnostic testing should be performed at the patient’s home. Four key requirements were identified: (1) A tele-connected home device with acceptable diagnostic performance and a supportive patient user interface, both hardware and software. (2) Automated analytics capabilities that can process large volumes of data. (3) Efficient remote patient engagement and support through a digital healthcare provider. (4) A low-cost medical system that enables digital healthcare delivery through appropriate compensation for both the monitoring provider and the prescribing physician services. We reviewed the published literature accompanying first the development of Preferential Hyperacuity Perimetry (PHP) for monitoring iAMD, followed by Spectral Domain Optical Coherence Tomography (SD-OCT) for monitoring nAMD. Emphasis was given to the review of the validation of the core technologies, the regulatory process, and real-world studies, and how they led to the release of commercial services that are covered by Medicare in the USA. We concluded that while during the first quarter of the 21st century, the two main pillars of management of AMD were anti-VEGF intravitreal injections and in-office OCT, the addition of home-monitoring-based digital health services can become the third pillar.

13 December 2024
Verified
Book Chapter
Open access
PDF file
Miguel Antonio BusquetsMiguel Antonio Busquets
Miguel Antonio Busquets
MRMuki Rapp
Muki Rapp
NMNishant Vision Mohan
Nishant Vision Mohan
Home OCT allows for individualized management of patients with exudative disease. Fluid dynamic heterogeneity demands the use of artificial intelligence to track data. This is accomplished with the Unet encoder-decoder segmentation network. Clinical trials have shown that home OCT demonstrates excellent adherence, self-imaging, automated fluid quantification with high sensitivity and specificity, and disease management refinement. AI and human grader correlation for the technology ranges between 91.6–100%. Decision-making data shows a potential impact on disease management, with a possible doubling of the average treatment interval (8–15.3 weeks), and recommended sooner treatment in 57% of patients. Two thirds of patients treated sooner required treatment within one week. Home OCT-derived analytics shows that patients treated within 7 days of disease reactivation had lower fluid volume at treatment, resolution time and fluid AUC (area under the curve).